Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Meanwhile, ARK sold 15,362 shares of Roku Inc (NASDAQ:ROKU) through its ARKK ETF, totaling $1,668,774. This marks a continuation of ARK’s recent trend of reducing its holdings in the streaming ...

Crispr stock jumped Monday while Intellia shares surged on promising updates for their gene-editing efforts in cholesterol ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $55.16, demonstrating a -2.56% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a ...

If you don’t want to get caught reacting to short-term market movements, you may want to invest in long-term growth trends — and few could be as transformative as artificial intelligence (AI). The ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!